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Synopsis
While the long-term physiological adaptation of the neuromuscular system to changed functional demands is usually
reflected by unilateral skeletal muscle transitions, the progressive degeneration of distinct motor neuron populations
is often associated with more complex changes in the abundance and/or isoform expression pattern of contractile
proteins and metabolic enzymes. In order to evaluate these intricate effects of primary motor neuronopathy on the
skeletal muscle proteome, label-free MS was employed to study global alterations in the WR (wobbler) mouse model
of progressive neurodegeneration. In motor neuron disease, fibre-type specification and the metabolic weighting of
bioenergetic pathways appear to be strongly influenced by both a differing degree of a subtype-specific vulnerability
of neuromuscular synapses and compensatory mechanisms of fibre-type shifting. Proteomic profiling confirmed this
pathobiochemical complexity of disease-induced changes and showed distinct alterations in 72 protein species,
including a variety of fibre-type-specific isoforms of contractile proteins, metabolic enzymes, metabolite transporters
and ion-regulatory proteins, as well as changes in molecular chaperones and various structural proteins. Increases
in slow myosin light chains and the troponin complex and a decrease in fast MBP (myosin-binding protein) probably
reflect the initial preferential loss of the fast type of neuromuscular synapses in motor neuron disease.
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INTRODUCTION
The continuum of mammalian skeletal muscles is characterized
by distinct fibre-type-specific differences in physiological, bio-
chemical and cellular properties [1–3] and this is reflected on
the molecular level by highly complex and differential protein
expression patterns [4–6]. Mature skeletal muscles exhibit a
remarkable potential to adapt to changed functional demands,
which is illustrated by swift transitions of muscle phenotypic pro-
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files in response to altered neuromuscular activity levels [7–9].
While enhanced neuromuscular activity or chronic low-frequency
electrostimulation causes a stepwise fast-to-slow transformation
process in skeletal muscle, disuse-related muscular atrophy or
complete denervation is typically associated with slow-to-fast
transitions [10–14]. The detailed biochemical analysis of the sar-
comeric myosin heavy chains has shown that hyper-excitability,
denervation or muscular dystrophy cause very different changes
in the isoform expression patterns of this essential contractile pro-
tein in skeletal muscles [15]. These biochemical consequences of
c© 2014 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/)
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fibre-type shifting are also evident by proteome-wide alterations
in the abundance and isoform expression pattern of contractile
proteins and metabolic enzymes, as outlined in several recent
reviews on MS-based skeletal muscle proteomics [16–18]. The
pathophysiology of preferential alterations in fibre innervation,
such as observed during paralysis in motor neuron disease, ap-
pears to be associated with less unilateral changes in muscle
fibres [19] and the denervation–reinnervation patterns in neuro-
genic atrophy are also associated with the presence of small
fibres and the expression of immature isoforms of myosin heavy
chains [20]. This complexity of molecular changes therefore re-
quires systematic approaches for the comprehensive analysis of
progressive neurodegeneration and its down-stream effects on
contractile fibres within the affected motor units [21].
Motor neuron diseases are a heterogeneous group of neuro-
degenerative syndromes, such as hereditary spastic paralysis,
primary lateral sclerosis, spastic paraplegia, spinobulbar mus-
cular atrophy and ALS (amyotrophic lateral sclerosis). A highly
progressive adult-onset loss of lower and upper motor neurons
resulting in paralysis is characteristic of ALS and can be of ge-
netic origin or be sporadic in nature [22–24]. Muscular atrophy
leads to limb and bulbar muscle weakness and respiratory in-
sufficiency. Various genes were shown to be involved in inher-
ited forms of ALS, including SOD1 (superoxide dismutase 1),
TARDBP, FUS, VCP, OPTN, ALS2, SETX, C9ORF72, PFN1,
VAPB, UBQLN2 and ANG [25–28]. Genomic, transcriptomic,
proteomic and metabolomic screening programmes have been
initiated to determine global changes in ALS specimens and
animal models of motor neuron disease [29,30] and to estab-
lish novel biomarkers for diagnostic, prognostic and therapeutic
applications [31,32]. Proteomic profiling of the effects of pro-
gressive neurodegeneration has included cerebrospinal fluid, cer-
vical spinal cord specimens, lumbar spinal cord preparations and
skeletal muscles [33–40].
Rodent models of motor neuron disease play a crucial role in
ALS research, as recently reviewed by McGoldrick et al. [41],
including the WR (wobbler) mouse (genotype wr/wr, phenotype
WR) [42,43]. The WR mouse exhibits progressive neurodegener-
ation and neuroinflammation [44–46] and is frequently used as an
ALS model for testing novel pharmacological approaches [47–
49], although no human neurodegenerative disease has yet been
identified that exhibits the same genetic abnormality [50]. The
primary alteration in the WR genotype has been identified as a
missense mutation in the ubiquitously expressed gene Vps54 that
leads to a leucine-to-glutamine replacement (L967Q) near the C-
terminus of the 977 amino acid polypeptide chain of VPS54 [51].
The vesicular protein sorting factor VPS54 represents an essen-
tial component of the hetero-trimeric GARP (Golgi-associated
retrograde protein) complex and the hydrophobic-to-hydrophilic
amino acid exchange in its primary sequence causes destabiliza-
tion of its tertiary protein structure leading to a reduction in the
concentration levels of VPS54 [52].
In analogy to the previous gel-based survey of the WR and
SOD mouse models of ALS, using fluorescence 2D difference
in-gel electrophoresis [39,40], we have used here a complement-
ary gel-free method, i.e. label-free MS, to determine secondary
changes in WR skeletal muscle tissue due to abnormal expres-
sion of the GARP component VPS54. The proteomic analysis
verified the complexity of neurodegeneration-related changes in
skeletal muscle from the WR mouse model of ALS and identified
novel changes in proteins involved in fibre contraction, energy
metabolism, metabolite transportation, ion handling, structural
integrity and the cellular stress response.
MATERIALS AND METHODS
Materials
Materials and analytical-grade chemicals used for the mass spec-
trometric analysis of WR versus WT (wild-type) skeletal muscle
tissues were obtained from Amersham Biosciences/GE Health-
care and BioRad Laboratories. The proteolytic enzymes Lys-C
and trypsin were purchased from Promega. Protease inhibitors
and chemiluminescence substrate were from Roche Diagnostics.
Whatman nitrocellulose transfer membranes were obtained from
Invitrogen. Primary antibodies were purchased from Abcam
[ab55559 to MBP (myosin-binding protein) C; ab97708 to tro-
ponin TnT; ab48003 to MLC2 (myosin light-chain 2); ab8592 to
desmin; ab41803 to annexin; ab26300 to lamin; ab6588 to col-
lagen; ab13496 to αB-crystallin; ab85366 to carbonic anhydrase
CA3; ab43176 to ATP-synthase; ab36329 to isocitrate dehydro-
genase; and ab28172 to prohibitin] and Sigma Chemical Com-
pany (L-9393 to laminin). Secondary peroxidase-conjugated sec-
ondary antibodies were obtained from Chemicon International.
All other chemicals were analytical grade and purchased from
Sigma Chemical Company.
WR mouse model of motor neuron disease
The origin of the WR stock and breeding of mice at Aarhus Uni-
versity has been previously described [53]. In this comparative
study, 9-week-old WR mice and age-matched normal C57 mice
were used. Animals were bred in accordance with Danish law on
the protection of laboratory animals and approved by the local
authorities. Mice were sacrificed by cervical dislocation and all
biochemical and proteomic studies were carried out with post-
mortem tissue samples.
Preparation of tissue extracts from WR and WT
muscle
Muscles from the hind limb of WR and WT mice were freshly
dissected, quick-frozen in liquid nitrogen, transported on dry
ice and then stored at − 80 ◦C prior to usage. Equal amounts
of tissue (100 mg wet weight) were employed for the prepara-
tion of muscle extracts. Skeletal muscle tissue was homogen-
ized using a hand-held IKA T10 Basic Homogenizer (IKA-
Labortechnik). Crude extracts were then incubated for 2.5 h at
room temperature with agitation using a Thermomixer from Ep-
pendorf. Samples were centrifuged at 4 ◦C for 20 min at 14 000 g
and the urea-soluble protein containing-middle layer was retained
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for further analysis [54]. For comparative proteomic profiling,
skeletal muscle homogenates from WR mice (n = 4) and WT
mice (n = 4) were pre-treated with the Ready Prep 2D clean
up kit from BioRad Laboratories. The resulting protein pellets
were resuspended in label-free solubilization buffer, consisting
of 10 mM Tris, pH 8.0, 6 M urea and 2 M thiourea in LC (li-
quid chromatography)–MS grade water [55]. Following vortex-
ing, sonication and centrifugation, the protein concentration of
the WR and WT suspensions was determined. Volumes of protein
suspensions were equalized using label-free solubilization buffer
and then reduced for 30 min with 10 mM DTT (dithiothreitol) and
alkylated for 20 min in the dark with 25 mM iodoacetamide in
50 mM ammonium bicarbonate. The proteolytic digestion of pro-
teins was carried out in two steps. First, digestion was performed
with sequencing grade Lys-C at a ratio of 1:100 (protease/protein)
for 4 h at 37 ◦C, followed by a dilution with four times the ini-
tial sample volume in 50 mM ammonium bicarbonate. Secondly,
further digestion was based on incubation with sequencing grade
trypsin at a ratio of 1:25 (protease/protein) overnight at 37 ◦C.
The protease-treated muscle protein suspensions were diluted
3:1 (v/v) with 2 % (v/v) TFA (trifluoroacetic acid) in 20 % (v/v)
acetonitrile. To ensure an even suspension of peptide populations
from WR versus WT muscle, the samples were briefly vortexed
and sonicated [55].
Label-free LC–MS/MS analysis
The nano LC–MS/MS analysis of WR versus WT samples was
carried out with the help of an Ultimate 3000 nanoLC system
(Dionex) coupled to an LTQ Orbitrap XL mass spectrometrer
(Thermo Fisher Scientific) in the Proteomics Facility of the Na-
tional Institute for Cellular Biotechnology, Dublin City Univer-
sity. The optimized methodology has been previously described
in detail [56,57]. Peptide mixtures (5 μl volume) were loaded
onto a C18 trap column (C18 PepMap, 300 μm id×5 mm, 5 μm
particle size, 100 ˚A pore size; Dionex). Desalting was achieved
at a flow rate of 25 μl/min in 0.1 % TFA for 10 min. The trap
column was switched on-line with an analytical PepMap C18
column (75 μm id×500 mm, 3 μm particle and 100 ˚A pore size;
Dionex). Peptides generated from muscle proteins were eluted
with the following binary gradients: solvent A [2 % (v/v) ACN
(acetonitrile) and 0.1 % (v/v) formic acid in LC–MS grade water]
and 0–25 % solvent B (80 % ACN and 0.08 % (v/v) formic acid
in LC–MS grade water) for 240 min and 25–50 % solvent B for
a further 60 min. The column flow rate was set to 350 nl/min
[56]. Data were acquired with Xcalibur software, version 2.0.7
(Thermo Fisher Scientific). The MS apparatus was operated in
data-dependent mode and externally calibrated. Survey MS scans
were acquired in the Orbitrap in the 300–2000 m/z range with the
resolution set to a value of 30 000 at m/z 400 and lock mass
set to 445.120025 u. CID (collision-induced dissociation) frag-
mentation was carried out in the linear ion trap with the three
most intense ions per scan [56]. Within 60 s, a dynamic exclu-
sion window was applied. A normalized collision energy of 35 %,
an isolation window of 3 m/z and one microscan were used to
collect suitable tandem mass spectra [57].
Quantitative profiling by label-free LC–MS/MS
analysis
Processing of the raw data generated from LC–MS/MS analysis
was carried out with Progenesis label-free LC–MS software (ver-
sion 3.1; Non-Linear Dynamics). Data alignment was based on
the LC retention time of each sample, allowing for any drift in
retention time given and adjusted retention time for all runs in the
analysis [56]. A reference run was established with the sample run
that yielded most features (i.e. peptide ions). The retention times
of all of the other runs were aligned to this reference run and peak
intensities were then normalized. Prior to exporting the MS/MS
output files to MASCOT (www.matrixscience.com) for protein
identification, a number of criteria were employed to filter the
data including: (i) peptide features with ANOVA<0.05 between
experimental groups; (ii) mass peaks (features) with charge states
from + 2, + 3; and (iii) greater than one isotope per peptide [55].
A MASCOT generic file was generated from all exported MS/MS
spectra from Progenesis software. The MASCOT generic file
was used for peptide identification with MASCOT (version 2.2)
and searched against the UniProtKB-SwissProt database (down-
loaded in January 2013) with 16 638 proteins (taxonomy: Mus
musculus). The following search parameters were used for pro-
tein identification: (i) MS/MS mass tolerance set at 0.5 kDa; (ii)
peptide mass tolerance set to 20 ppm; (iii) carbamidomethylation
set as a fixed modification; (iv) up to two missed cleavages were
allowed; and (v) methionine oxidation set as a variable modi-
fication. For further consideration and reimportation back into
Progenesis LC–MS software for further analysis, only peptides
with ion scores of 40 and above were chosen [57]. Importantly,
the following criteria were applied to assign a skeletal muscle-
associated protein as properly identified: (i) an ANOVA score
between experimental groups of0.05; (ii) proteins with2 pep-
tides matched; and (iii) a MASCOT score >40 [55,56]. Standard
bioinformatics software was used to identify the clustering of
molecular functions of the MS-identified muscle proteins with
a changed abundance in WR mouse. These analyses were per-
formed with the PANTHER (http://pantherdb.org; version 8.1)
comprehensive database of protein families for the cataloguing
of molecular functions [58].
Independent verification of key proteomic findings
by immunoblot analysis
Immunoblotting was used to confirm changed concentration
levels of distinct muscle-associated proteins, as revealed by label-
free LC–MS/MS analysis. Routine 1D gel electrophoresis and
subsequent immunoblot analysis was performed by established
methods [53]. The electrophoretic separation of WR and WT
hind limb muscle samples was carried out with standard 10 %
(w/v) PAGE gels, followed by wet transfer at 100 V for 70 min
to Whatman Protan nitrocellulose sheets in a Transblot Cell from
BioRad Laboratories. To prevent non-specific antibody binding,
membrane sheets were blocked for 1 h with a milk protein solu-
tion consisting of 5 % (w/v) non-fat dried skimmed milk powder
in phosphate-buffered saline. Incubation with sufficiently diluted
primary antibodies to a variety of identified muscle proteins
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were carried out for a minimum of 3 h with gentle agitation
at 4 ◦C, followed by several washing steps and then incubation
for 1 h at room temperature with sufficiently diluted peroxidase-
conjugated secondary antibodies [55]. Following washing of
membranes, the visualization of immuno-decorated protein bands
was performed with the enhanced chemiluminescence method.
The densitometric scanning and quantitative evaluation of im-
munoblots was carried out with an HP PSC-2355 scanner and
GraphPad Prism and ImageJ (NIH) software.
RESULTS
The MS-based proteomic analysis of 9-week-old WR hind limb
muscle versus age-matched WT muscle was performed in order
to establish the extent of altered protein concentrations in an es-
tablished mouse model of motor neuron disease. Protein changes
were determined by label-free LC–MS/MS analysis and altera-
tions in proteomic hits of interest were confirmed by comparative
immunblotting.
Label-free LC–MS/MS analysis of WR versus WT
hind limb muscle
The proteomic profiling of the WR muscle showed significant
alterations in the abundance of 72 proteins species. As listed
in Table 1, a decrease was determined for nine proteins and an
increased concentration was found in the case of 63 proteins.
Changes of 2-fold or higher were observed for 20 increased pro-
teins and two decreased proteins. More moderate alterations in
the expression levels occurred in 50 other muscle-associated pro-
teins. Proteins that exhibited a considerable increase in the con-
centration were identified as a variety of contractile elements,
including myosin light chains, troponin subunits TnI, TnC and
TnT, and tropomyosin. In addition, the nuclear envelope pro-
tein lamin, the mitochondrial enzyme aldehyde dehydrogenase,
histone protein H4, the molecular chaperone αB-crystallin, fatty
acid-binding protein, fructose-1,6-bisphosphatase, four and a half
LIM domains protein 1, carbonic anhydrase CA3, heat shock pro-
tein beta-1, annexin and peptidyl-prolyl cis–trans isomerase A
were drastically increased in WR muscle. The haemoglobin sub-
units alpha and beta were both shown to be approximately 2-fold
increased, suggesting that the WR and WT muscle fibres of hind
limbs are possibly not equally well vascularized. The increased
levels of haemoglobin may be due to higher levels of blood sup-
ply to WR muscles. However, since the animals had not been
perfused prior to sacrificing, it is also possible that this result is
an artefact of the isolation procedure and therefore both the WR
and WT tissues may be equally well vascularized.
An overview of protein expression changes in WR muscle
is graphically presented in Figure 1. Muscle proteins associated
with the contractile apparatus, metabolic pathways, metabolite
transport, ion handling, structural maintenance and the cellu-
lar stress response are shown. Decreased proteins and increased
proteins are shown in the lower and upper parts of the graph, re-
spectively. Muscle proteins that have been identified by label-free
MS analysis are symbolized by solid circles and proteins previ-
ously characterized by gel-based proteomics [39] are marked by
a rhombus. While the previous application of fluorescence dif-
ference in-gel electrophoresis resulted in the identification of 14
changed proteins, with several proteins being recognized to be
present in more than one protein spot [39], the label-free MS
analysis determined altered expression levels in a considerably
larger number of proteins. The fact that the previously identified
increase in glyceraldehyde-3-phosphate dehydrogenase was not
recognized by label-free MS analysis could be due the fact that
the protein is better separated by 2D gel electrophoresis as com-
pared with LC and/or that this glycolytic protein digests in an
optimum way by in-gel methodology to produce large numbers
of detectable peptides. Both proteomic techniques established
similar findings for the fast isoform of MBP-C, actinin, actin,
troponin and myosin light chain [39]. The application of the
bioinformatics PANTHER database of protein families [58] re-
vealed a list of molecular functions of the newly identified WR
muscle proteins with an altered concentration. Figure 2 shows
the cataloguing of the proposed functions in a pie chart: trans-
porter activity (4.8 %), antioxidant activity (1 %), binding activ-
ity (21.9 %), catalytic activity (25.7 %), enzyme regulator activ-
ity (5.7 %), ion channel activity (2.9 %), motor activity (3.8 %),
receptor activity (4.8 %), structural molecule activity (24.8 %),
transcription regulator activity (2.9 %) and translation regulator
activity (1.9 %).
Verification of proteomic findings by comparative
immunoblotting of WR versus WT hind limb muscle
preparations
Following the MS identification of protein changes in WR leg
muscle, a variety of proteomic hits were verified by immun-
oblot analysis (Figures 3–6). This included marker proteins of
the contractile apparatus, the cytoskeleton, the nuclear envel-
ope, the extracellular matrix, the cellular stress response, muscle
metabolism, mitochondrial bioenergetics and mitochondrial reg-
ulation. Figure 3 shows a silver-stained gel of four biological
repeats of preparations from WR versus WT muscle, illustrat-
ing equal protein loading and relatively comparable protein band
patterns in the two different muscle specimens. Immunoblotting
with an antibody to laminin demonstrated comparable levels of
this major extracellular matrix protein in atrophying and normal
muscle samples (Figures 3B and 3C).
In contrast, significant concentration changes were confirmed
for a range of muscle-associated proteins. While MBP-C was
decreased in WR muscle (Figures 4A and 5A), the contract-
ile proteins troponin TnT and MLC2 exhibited increased levels
(Figures 4B, 4C; 5B, 5C). The nuclear envelope protein lamin, the
cytoskeletal element desmin and the matrix–cell interaction pro-
tein annexin showed an increased concentration in WR muscle
(Figures 4D–4F and 5D–5F). In contrast to the unchanged levels
of the basal lamina component laminin (Figures 3B and 3C),
collagen was found to be increased in WR muscle (Figures 4G
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
334 c© 2014 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/)
which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
Muscle proteomics of primary motor neuronopathy
Table 1 List of proteins with a changed concentration in WR leg muscle as revealed by label-free mass spectrometry
Accession number Protein name Peptides Score ANOVA Fold change
P05977 Myosin light-chain MLC1/3, muscle 2 126.35 0.0187 179.27
Q9WUZ5 Troponin I, slow 3 180.85 0.0047 7.91
P19123 Troponin C, slow 4 296.17 0.0016 6.25
O88346 Troponin T, slow 3 181.3 0.0050 6.09
P21107 Tropomyosin, alpha-3 chain 4 438.44 0.0020 4.69
Q91Z83 Myosin-7 (MyHC slow) 33 3080.77 0.0012 4.30
P51667 Myosin light-chain MLC2, cardiac 5 270.34 0.0086 3.90
P48678 Prelamin-A/C 9 592.98 0.0034 2.93
P47738 Aldehyde dehydrogenase, mitochondrial 4 236.63 0.0020 2.93
P09542 Myosin light-chain MLC3 4 365.98 0.0143 2.75
P62806 Histone H4 3 228.77 0.0010 2.59
P23927 αB-Crystallin (HSPB5) 3 170.51 0.0088 2.57
P04117 Fatty acid-binding protein, adipocyte 3 261.47 0.0007 2.48
P70695 Fructose-1,6-bisphosphatase isozyme 2 2 109.38 0.0013 2.34
P97447 Four and a half LIM domains protein 1 3 187.59 0.0030 2.34
P02088 Haemoglobin, subunit beta-1 5 480.94 0.0103 2.30
P16015 Carbonic anhydrase CA3 6 521.62 0.0152 2.23
P14602 Heat shock protein beta-1 (HSPB1, Hsp27) 3 153.41 0.0004 2.22
P07356 Annexin A2 3 159.34 0.0196 2.04
P17742 Peptidyl-prolyl cis–trans isomerase A 3 171.81 0.0231 1.99
Q8VHX6 Filamin-C 20 1399.68 0.0003 1.95
P60710 Actin, cytoplasmic 1 4 393.11 0.0327 1.89
P01942 Haemoglobin, subunit alpha 4 388.07 0.0192 1.89
P67778 Prohibitin 2 114.26 0.0210 1.83
P54071 Isocitrate dehydrogenase [NADP], mitochondrial 3 248.98 0.0024 1.72
P20152 Vimentin 6 347.23 0.0105 1.68
Q9JI91 Alpha-actinin-2 16 1373.39 0.0008 1.64
Q9D0K2 Succinyl-CoA:3-ketoacid coenzyme A transferase 1,
mitochondrial
2 89.7 0.0041 1.63
Q9JKB3 DNA-binding protein A 2 167.62 0.0021 1.63
O08539 Myc box-dependent-interacting protein 1 4 215.92 0.0067 1.60
P07724 Serum albumin 11 792.98 0.0006 1.56
P20029 78 kDa glucose-regulated protein 2 225.91 0.0033 1.55
P62259 14-3-3 protein epsilon 3 188.9 0.0091 1.55
P31001 Desmin 9 705.13 0.0041 1.54
Q04857 Collagen, alpha-1(VI) chain 4 267.81 0.0146 1.52
P10126 Elongation factor 1-alpha 1 3 171.89 0.0294 1.50
Q02788 Collagen, alpha-2(VI) chain 5 317.3 0.0306 1.49
Q99JY0 Trifunctional enzyme subunit beta, mitochondrial 7 497.11 0.0060 1.49
P51885 Lumican 2 126.04 0.0145 1.49
P11499 Heat shock protein HSP 90-beta (HSPC) 5 375.59 0.0060 1.47
Q7TQ48 Sarcalumenin 6 381.25 0.0039 1.47
P51174 Long-chain specific acyl-CoA dehydrogenase, mitochondrial 3 165.65 0.0004 1.44
Q9JIF9 Myotilin 4 296.4 0.0063 1.43
Q61171 Peroxiredoxin-2 2 119.91 0.0228 1.40
P63038 60 kDa heat shock protein, mitochondrial 2 135.87 0.0034 1.39
P58252 Elongation factor 2 3 194.77 0.0121 1.39
Q8QZT1 Acetyl-CoA acetyltransferase, mitochondrial 2 134.75 0.0020 1.38
P68372 Tubulin beta-4B chain 2 548.87 0.0045 1.36
Q8BMS1 Trifunctional enzyme subunit alpha, mitochondrial 6 360.96 0.0166 1.36
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Table 1 Continued
Accession number Protein name Peptides Score ANOVA Fold change
Q99LC5 Electron transfer flavoprotein subunit alpha, mitochondrial 2 210.91 0.0181 1.35
P05202 Aspartate aminotransferase, mitochondrial 2 109.34 0.0083 1.32
Q91ZJ5 UTP-glucose-1-phosphate uridylyltransferase 2 117.55 0.0095 1.31
P56480 ATP synthase, subunit beta, mitochondrial 6 463.83 0.0263 1.31
Q9JKS4 LIM domain-binding protein 3 2 163.43 0.0020 1.29
P50544 Very long-chain specific acyl-CoA dehydrogenase,
mitochondrial
4 261.63 0.0019 1.29
P38647 Stress-70 protein, mitochondrial 2 108.01 0.0009 1.27
Q9D2G2 Dihydrolipoyllysine-residue succinyltransferase component of
2-oxoglutarate dehydrogenase complex, mitochondrial
2 98.57 0.0163 1.26
Q99KI0 Aconitate hydratase, mitochondrial 5 304.47 0.0168 1.26
Q9DB20 ATP synthase subunit O, mitochondrial 2 117.63 0.0425 1.25
P63017 Heat shock cognate 71 kDa protein 4 407.65 0.0170 1.24
Q9DCW4 Electron transfer flavoprotein, subunit beta 3 201.29 0.0171 1.24
Q03265 ATP synthase subunit alpha, mitochondrial 4 365.7 0.0168 1.23
Q62234 Myomesin-1 3 176.76 0.0467 1.22
O88990 Alpha-actinin-3 4 431.15 0.0131 0.83
Q9WUB3 Glycogen phosphorylase, muscle 5 343.1 0.0130 0.79
A2ASS6 Titin 42 2579.98 0.0005 0.79
Q9D0F9 Phosphoglucomutase-1 6 438.29 0.0105 0.75
Q3V1D3 AMP deaminase 1 3 218.71 0.0271 0.73
Q8R429 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 5 398.2 0.0042 0.61
Q5SX39 Myosin-4, Mus musculus 4 990.28 0.0179 0.55
Q5XKE0 Myosin-binding protein C, fast-type 4 268.17 0.0291 0.51
P07759 Serine protease inhibitor A3K 2 154.17 0.0086 0.28
Figure 1 Overview of alterations in WR muscle proteins
The graph shows the change in concentrations of muscle proteins identified by MS-based proteomics. Decreased versus
increased proteins are shown in the lower and upper part of the graph, respectively. Proteins that have been identified
by label-free MS analysis are marked by a solid circle and proteins which concentration changes have previously been
established by fluorescence 2D in-gel electrophoretic analysis [39] are marked by a rhombus.
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Figure 2 Molecular function of WR muscle proteins with a
changed abundance
Publically available bioinformatics software was used to identify the
clustering of molecular functions of MS-identified muscle proteins with
a changed abundance in the WR mouse model of ALS (Table 1). The
analysis was performed with the PANTHER database (version 8.1) of
protein families for the cataloguing of molecular functions [58].
and 5G). In agreement with cellular stress and modifications of
the contractile apparatus, a drastically increased concentration of
αB-crystallin was confirmed by antibody decoration (Figures 4H
and 5H). In addition, the enzymes carbonic anhydrase CA3, mi-
tochondrial ATP synthase and isocitrate dehydrogenase, as well
as the regulatory protein prohibitin exhibited changes in their ex-
pression levels (Figures 4I–4L and 5I–5L) in agreement with the
proteomic results listed in Table 1.
Figure 6 summarizes the immunoblot analysis of three crucial
Ca2 + -binding proteins, i.e. the cytosolic protein parvalbumin,
the luminal Ca2 + -shuttle protein sarcalumenin and the abundant
Ca2 + -buffering protein calsequestrin of the terminal cisternae
region of the SR (sarcoplasmic reticulum). While parvalbumin
was shown to be greatly reduced in WR muscle (Figures 6A
and 6B), the luminal Ca2 + -binding proteins exhibited increased
levels in atrophying muscle preparations (Figures 6C–6F).
DISCUSSION
Distinct changes in innervation patterns have a profound influ-
ence on skeletal muscle differentiation, fibre regeneration and
the reprogramming of motor units during physiological adapta-
tions to changed functional demands. The proteomic profiling of
muscle plasticity has established discrete changes in the abund-
ance and expression pattern of contractile proteins and metabolic
enzymes during myogenesis and fibre maturation, as well as in
response to enhanced neuromuscular activity, disuse-associated
atrophy or chronic electrostimulation [18]. Here, we have used the
WR mouse model of primary neuronopathy [43,51] to evaluate
the complexity of proteome-wide changes in response to disease-
induced alterations in fibre innervation. The label-free MS ana-
lysis of proteome-wide changes in neurogenic muscular atrophy
has noticeably shown that distinct differences exist between the
effects of nerve crush or complete denervation of skeletal muscles
versus the influences of progressive degeneration of discrete mo-
tor neuron populations. The downstream biochemical effects of
Figure 3 Electrophoretic analysis of WR and WT muscle preparations used for LC–MS/MS analysis
Shown are a silver-stained 1D gel (A) and a representative immunoblot with an expanded view of immuno-decorated bands
labelled with an antibody to laminin (B). Lane 1 shows MM (molecular mass) standards with their values in kDa on the
left side of the panel (A). Lanes 2–9 represent four biological repeats of WR versus normal WT muscle preparations,
respectively. The extracellular matrix protein laminin did not show significant changes in its concentration between WR
and WT muscle extracts (C).
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Figure 4 Immunoblot survey of proteins with a changed abundance in WR muscle as revealed by proteomics
Shown are representative immunoblots with expanded views of immuno-decorated bands labelled with antibodies to
MBP-C (A), troponin subunit TnT (B), myosin light chain MLC2 (C), desmin (D), annexin (E), lamin (F), collagen (G),
αB-crystallin (HSPB5) (H), carbonic anhydrase isoform CA3 (I), mitochondrial ATP synthase (J), isocitrate dehydrogenase
(K) and prohibitin (L). Lanes 1 and 2 represent WR versus WT muscle preparations, respectively.
Figure 5 Densitometric analysis of the immunoblot survey of proteins with a changed abundance in WR muscle
The comparative immunoblot analysis depicted in Figure 4 was statistically evaluated using an unpaired Student’s t test
(n = 5; *P< 0.05; **P< 0.01; ***P< 0.001).
altered innervation patterns on neuromuscular modulation are
clearly reflected by drastic changes in the concentration levels
of muscle proteins. Importantly, this study has established that
a more complex pattern of proteome-wide changes occurs in
disease-associated muscular atrophy as compared with muscular
disuse or denervation [18]. The proteomic analysis of WR muscle
agrees with the idea that fibre-type specification and the meta-
bolic weighting of bioenergetic pathways is clearly influenced
by both a differing degree of a subtype-specific vulnerability of
neuromuscular synapses and compensatory mechanisms of fibre-
type shifting in motor neuron disease. In general, experimental
denervation, traumatic nerve injury or prolonged neuromuscu-
lar disuse results in relatively unilateral skeletal muscle trans-
itions. While enhanced neuromuscular activity triggers a clear
fast-to-slow transition in skeletal muscle, disuse-related muscu-
lar atrophy or complete denervation is mostly associated with a
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Figure 6 Immunoblot analysis of Ca2+ -binding proteins with a changed abundance in WR muscle
Shown are representative immunoblots with expanded views of immuno-decorated bands labelled with antibodies to the
cytosolic Ca2 + -binding protein parvalbumin (A, B), the luminal Ca2 + -shuttle protein sarcalumenin of the SR (sarcoplasmic
reticulum) (C, D) and the luminal Ca2 + -binding protein calsequestrin of the terminal cisternae region of the SR (E, F).
Lanes 1 and 2 represent WR versus WT muscle preparations, respectively. The comparative immunoblot analysis was
statistically evaluated using an unpaired Student’s t test (n = 5; *P< 0.05; **P< 0.01).
slow-to-fast transformation. In contrast, the new proteomic data
presented here demonstrate that protein changes in motor neuron
disease are more complex and that this disease is not associ-
ated with a straightforward slow-to-fast transformation process.
Motor neuron disease appears to be associated with complex dif-
ferential expression patterns of both fast and slow muscle protein
isoforms.
In agreement with the findings of a previous DIGE-based ana-
lysis of WR muscle [39], disease-associated muscular atrophy
causes a reduced concentration of the fast MBP-C. Immunoblot
analysis has confirmed the lower concentration of this contractile
protein in WR muscle. In addition, the study presented here has
established a reduction in α-actinin, titin and myosin 4, the foetal
muscle isoform of MHCIIb, indicating remodelling of the cyto-
skeletal network and the auxiliary structure and contractile ele-
ments of the actomyosin apparatus [59]. The lower concentra-
tion of glycogen phosphorylase and phosphoglucomutase agrees
with the idea of a disturbed glucose metabolism in WR muscle.
However, the glycolytic enzyme fructose-1,6-bisphosphatase was
found to be increased in WR preparations, which was also shown
in a previous gel-based study of WR muscle [39]. Since some
glycolytic enzymes are multi-functional and are also poten-
tially involved in cellular signalling [60], the differential expres-
sion levels of individual glycolysis-related proteins may reflect
changes in other biochemical processes than anaerobic meta-
bolism [39,40]. The complex alterations in glycolytic and mi-
tochondrial muscle enzymes shown in this study indicate that
the metabolic transitions in WR muscle is more complex than a
unidirectional shift towards a particular bioenergetic phenotype.
Interestingly, the SERCA1 (sarcoplasmic/endoplasmic retic-
ulum Ca2 + -ATPase 1) isoform of the relaxation-inducing Ca2 + -
ATPase of the SR was identified by label-free MS analysis. This
finding illustrates suitably the advantages and complementary
nature of gel-free separation approaches in muscle proteomics
and shows that liquid chromatography-coupled MS analysis is
capable of detecting changes in integral and highly hydrophobic
muscle enzymes [61]. Since the Ca2 + -pumping ATPase is a relat-
ively abundant protein, it is difficult to interpret whether changes
in the SERCA1 isoform play a major role in the atrophy-related
fibre changes or represent a minor alteration within the extens-
ive network of the SR membrane system. Immunoblotting with
antibodies to the Ca2 + -ATPase from the SR resulted in excess-
ive background staining (not shown), which prevented a proper
verification of this proteomic finding. Interestingly, the concen-
tration of the luminal Ca2 + -binding proteins sarcalumenin and
calsequestrin is considerably increased in WR muscle, which
is indicative of a greater demand for Ca2 + -buffering within
the SR. A possible reason for this is the avoidance of Ca2 + -
dependent proteolysis and/or abnormal cellular signalling on the
level of excitation–contraction coupling, as is commonly ob-
served in muscular disorders [62]. As previously shown by im-
munoblotting and proteomics in the WR and SOD mouse models
of ALS [39,40], respectively, the concentration of the cytosolic
Ca2 + -binding protein parvalbumin is drastically lowered in mo-
tor neuron disease. This reduced capability of cytosolic Ca2 + -
buffering might be related to the increased levels of luminal
Ca2 + -binding capacity in WR muscle preparations and agrees
with previously described decreased mRNA levels of parvalbu-
min in the same animal model of ALS [63].
In contrast to the above outlined decreases in metabolic en-
zymes and contractile proteins, a large number of proteins were
found to be increased in WR muscle. This included proteins
involved in muscle contraction, the cytoskeleton, the extra-
cellular matrix, metabolite transportation, muscle metabolism,
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mitochondrial regulation, ion handling and the cellular stress re-
sponse. The immunoblot survey presented in this study has con-
firmed these concentration changes in a variety of marker proteins
of distinct subcellular regions of skeletal muscle tissue. Striking
increases were observed for several slow isoforms of myosin light
chains and the TnI, TnC and TnT subunits of the troponin com-
plex [59]. Thus, in divergence to unilateral slow-to-fast transitions
due to chronic unloading or experimental denervation procedures,
as shown by various proteomics studies [64–68], the increase in
slow forms of essential contractile proteins probably reflects an
initial preferential loss of the fast type of neuromuscular synapses
in the WR model of motor neuron disease. Increased levels of
a variety of mitochondrial components such as aldehyde dehyd-
rogenase, isocitrate dehydrogenase, prohibitin, succinyl-CoA:3-
ketoacid coenzyme A transferase, long-chain specific acyl-CoA
dehydrogenase, trifunctional enzyme, electron transfer flavopro-
tein, aspartate aminotransferase, acetyl-CoA acetyltransferase,
aconitate hydratase, oxoglutarate dehydrogenase and ATP syn-
thase would agree with this idea. These alterations are therefore
probably not directly related to an organized or adaptive pattern
of fibre-type shifting, but more likely based on the initial con-
sequence of a preferential loss of neuromuscular synapses that
normally function within a fast type of innervation process.
The raised levels of the nuclear envelope protein lamin-A/C
and the histone H4 protein indicate changes or restructuring of
muscle nuclei within select fibre populations of the WR mouse.
Lamin A/C and lamin B of the nuclear envelope form stabilizing
LINC complexes with SUN1/2 proteins and nesprins, which in
turn bind to cytoskeletal filaments [69]. Therefore an indirect link
might exist with respect to other changed muscle proteins, such
as filamin, desmin, tubulin and vimentin. Muscle-specific filamin
C acts as an actin cross-linking protein, desmin and vimentin
are intermediate filament components and tubulin constitutes an
essential protein of microtubules [70]. Their increased abund-
ance, as already previously reported [39], suggests a reorganiz-
ation of the muscle cytoskeleton and interior filament network
in response to neurodegeneration-related unloading. The extra-
cellular matrix protein collagen and the multi-functional protein
annexin A2, which binds to sarcolemmal dysferlin and is prob-
ably involved in cell–matrix interactions, were also shown to
be increased, which could be a compensatory response to sta-
bilize the weakened fibre periphery during disease-related fibre
unloading. Since the surface membrane-associated dystrophin–
glycoprotein complex and the neuromuscular junction-coupled
utrophin–glycoprotein complex are closely linked to the actin
membrane cytoskeleton [71], which is indirectly associated with
the complex cytoskeletal filaments within the muscle interior
and the outside structural support of the nuclear envelope, it
is possible that external stimuli affect the entire cytoskeletal
network of muscle fibres simultaneously, including the lamin-
associated LINC complex [69]. Thus, motor neuron disease ap-
pears to be associated with considerable changes in the extra-
cellular matrix, the actin cytoskeleton, intermediate filaments,
microtubules and the nuclear envelope.
Elevated levels of the molecular chaperones αB-crystallin
(HSPB5), Hsp27 (HSPB1, beta-1), the large heat shock pro-
tein HSP90-beta (HSPC), the stress-70 protein, the mitochondrial
78 kDa glucose-regulated protein, the mitochondrial 60 kDa heat
shock protein and the heat shock cognate 71 kDa protein are in-
dicative of considerable cellular stress levels in WR muscle and
the need for extensive refolding or the swift removal of misfolded
muscle proteins [72]. Increases in a variety of heat shock proteins
were also reported by Capitanio et al. [40] to occur in the SOD
mouse model of ALS. Thus, the missense mutation in the Vps54
gene that causes a L967Q replacement in the vesicular protein-
sorting factor VPS54 [51] triggers substantial cellular stress in
affected muscle tissues. The destabilization of the tertiary pro-
tein structure of VPS54 and subsequent reduction in its abund-
ance levels seems to severely disturb the function of the GARP
complex and indirectly trigger an extensive stress response. The
predominant initial effect on fast type synapses is substantiated by
the fact that increased amounts of the CA3 isoform of carbonic
anhydrase were identified in WR muscle. Since immunocyto-
chemical studies by Fremont et al. [73] have demonstrated higher
levels of carbonic anhydrase in soleus muscle as compared with
vastus lateralis muscle, possibly changes in muscle mass and
contractile function are focused initially on fast-twitching fibres
populations in motor neuron disease. Alternatively, the patho-
physiological changes in WR muscle may require an increased
demand for efficient CO2-removal during fibre remodelling.
Recently, early gene expression changes were studied by mi-
croarray screening of gastrocnemius muscle from the SOD1
mouse model of ALS [74]. The investigation identified differ-
ential gene activation levels in the Wnt/PI3K (phosphoinositide
3-kinase) signalling pathways and epithelial–mesenchymal trans-
itions in pre-symptomatic skeletal muscle. Since the PI3K path-
way is involved both in the inhibition of cell death and the promo-
tion of cell proliferation, the maintenance and repair of affected
fibre populations may be impaired. Glucose uptake and fiber dif-
ferentiation may also be altered, agreeing with the general idea of
motor neuron disease being a multisystem disorder with a defect-
ive muscle metabolism. The gene expression changes observed
in the gastrocnemius muscle of SOD1-G93A transgenic mice
suggest that neuromuscular impairments precede motor neuron
death at pre-symptomatic periods of motor neuron disease [74].
The analysis of muscle biopsies from ALS patients identified in-
teresting alterations in the gene expression patterns in this form
of motor neuron disease, including elevated levels of mRNA en-
coding myosin-8, collagen, actin and annexin [75]. Decreased
mRNA levels of actinin alpha-3 and the fast isoform of MPB-
C agree with the findings from this proteomic study. Since de-
creased levels of fast MBP-C were shown to occur in degenerating
muscle by both label-free MS analysis and gel-based proteomics
[39], as well as transcriptomic analysis of ALS muscle biopsies
[75], this protein represents an excellent new candidate of an
internal muscle-associated biomarker of motor neuron disease.
Other transcriptomic analyses have focused on the spinal cord
from animal models and ALS patients [76–78]. Altered patterns
of cell adhesion, the immune response, lipid metabolism and in-
flammation were shown to be involved in the onset of progressive
paralysis, muscular atrophy and a hypermetabolic state in motor
neuron disease [78].
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In conclusion, certain pathophysiological mechanisms involve
the preferential loss of motor neurons and/or are associated with
defective re-innervation patterns, such as muscle ageing or motor
neuron diseases. Although primary motor neuronopathies evid-
ently lead to muscular atrophy, the effect of progressive neuro-
degeneration on the contractile phenotype or bioenergetics pro-
cesses is not as one sided as in the case of complete denervation.
The preferential loss of certain types of motor neurons exerts a
differential effect on fibre-type specification and metabolic path-
ways. The label-free MS analysis presented here could show that,
in contrast to the characteristic slow-to-fast transitions associated
with disuse-related muscular atrophy or denervation-associated
fibre wasting, motor neuron disease exhibits more complex pro-
tein alterations on the level of metabolic enzymes and contractile
proteins. There certainly exists a distinct link between changed
neuromuscular functions and complex proteome-wide alterations
in skeletal muscle. The newly identified alterations in muscle
proteins can now be exploited as novel diagnostic, prognostic
or therapeutic targets to improve the evaluation and treatment of
motor neuron disease. Especially striking is the drastic reduc-
tion in the fast isoform of MBP-C [39,75], making this protein
isoform a good candidate to be exploited as a new marker for
designing improved assay systems.
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